$NKTR
NEKTAR THERAPEUTICS

2012 Q4 Form 10-Q Financial Statement

#000119312512463220 Filed on November 09, 2012

View on sec.gov

Income Statement

Concept 2012 Q4 2012 Q3 2011 Q3
Revenue $21.15M $18.41M $27.07M
YoY Change 33.99% -31.98% -28.58%
Cost Of Revenue $7.290M $7.228M $5.038M
YoY Change 33.76% 43.47% -18.74%
Gross Profit $13.86M $11.18M $22.03M
YoY Change 34.11% -49.23% -30.5%
Gross Profit Margin 65.53% 60.74% 81.39%
Selling, General & Admin $10.90M $10.10M $12.40M
YoY Change -5.22% -18.55% 21.57%
% of Gross Profit 78.67% 90.31% 56.29%
Research & Development $46.37M $34.02M $31.02M
YoY Change 39.25% 9.67% 11.98%
% of Gross Profit 334.68% 304.15% 140.8%
Depreciation & Amortization $3.900M $3.600M $3.800M
YoY Change 8.33% -5.26% -9.52%
% of Gross Profit 28.15% 32.19% 17.25%
Operating Expenses $46.37M $34.02M $31.02M
YoY Change 39.25% 9.67% -18.37%
Operating Profit -$43.38M -$32.90M -$21.34M
YoY Change 25.86% 54.19% 238.7%
Interest Expense -$9.600M $5.697M $2.543M
YoY Change 317.39% 124.03% -215.59%
% of Operating Profit
Other Income/Expense, Net -$10.43M -$2.638M
YoY Change 295.19%
Pretax Income -$53.00M -$43.33M -$23.98M
YoY Change 44.02% 80.7% 185.43%
Income Tax $0.00 $222.0K $92.00K
% Of Pretax Income
Net Earnings -$52.93M -$43.55M -$24.07M
YoY Change 41.15% 80.93% 176.64%
Net Earnings / Revenue -250.29% -236.51% -88.92%
Basic Earnings Per Share
Diluted Earnings Per Share -$459.2K -$378.6K -$210.7K
COMMON SHARES
Basic Shares Outstanding 115.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2012 Q4 2012 Q3 2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $277.2M $319.3M $266.5M
YoY Change 14.93% 19.81% -12.13%
Cash & Equivalents $25.44M $10.34M $43.01M
Short-Term Investments $251.8M $308.9M $223.5M
Other Short-Term Assets $13.36M $7.003M $7.600M
YoY Change -25.53% -7.86% 24.59%
Inventory $18.27M $16.75M $10.70M
Prepaid Expenses
Receivables $5.805M $3.911M $12.90M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $314.6M $346.9M $297.6M
YoY Change 13.71% 16.58% -8.82%
LONG-TERM ASSETS
Property, Plant & Equipment $72.22M $73.26M $81.60M
YoY Change -8.1% -10.23% -16.48%
Goodwill $76.50M $76.50M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $0.00 $35.00M $191.5M
YoY Change -100.0% -81.72%
Other Assets $9.443M $9.728M $800.0K
YoY Change 845.25% 1116.0% -57.89%
Total Long-Term Assets $183.2M $194.5M $350.5M
YoY Change -44.47% -44.51% 99.03%
TOTAL ASSETS
Total Short-Term Assets $314.6M $346.9M $297.6M
Total Long-Term Assets $183.2M $194.5M $350.5M
Total Assets $497.8M $541.5M $648.1M
YoY Change -17.93% -16.46% 28.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.863M $2.624M $2.200M
YoY Change -5.17% 19.27% -50.0%
Accrued Expenses $8.008M $6.450M $37.10M
YoY Change 20.08% -82.61% 3.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $215.0M
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $78.54M $69.47M $279.0M
YoY Change -71.5% -75.1% 229.01%
LONG-TERM LIABILITIES
Long-Term Debt $136.6M $264.2M $15.30M
YoY Change 835.62% 1626.8% -93.42%
Other Long-Term Liabilities $10.81M $10.73M $123.0M
YoY Change 51.01% -91.28% 57.09%
Total Long-Term Liabilities $10.81M $10.73M $138.3M
YoY Change 51.01% -92.24% -55.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $78.54M $69.47M $279.0M
Total Long-Term Liabilities $10.81M $10.73M $138.3M
Total Liabilities $450.8M $446.1M $417.3M
YoY Change 10.28% 6.91% 5.51%
SHAREHOLDERS EQUITY
Retained Earnings -$1.570B -$1.517B
YoY Change 12.29%
Common Stock $1.618B $1.613B
YoY Change 1.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $47.02M $95.33M $230.8M
YoY Change
Total Liabilities & Shareholders Equity $497.8M $541.5M $648.1M
YoY Change -17.93% -16.46% 28.98%

Cashflow Statement

Concept 2012 Q4 2012 Q3 2011 Q3
OPERATING ACTIVITIES
Net Income -$52.93M -$43.55M -$24.07M
YoY Change 41.15% 80.93% 176.64%
Depreciation, Depletion And Amortization $3.900M $3.600M $3.800M
YoY Change 8.33% -5.26% -9.52%
Cash From Operating Activities -$47.40M -$27.20M -$21.80M
YoY Change 12.32% 24.77% -1.8%
INVESTING ACTIVITIES
Capital Expenditures -$4.900M -$2.500M -$1.500M
YoY Change 250.0% 66.67% -88.81%
Acquisitions
YoY Change
Other Investing Activities $67.10M -$2.900M $54.10M
YoY Change 322.01% -105.36% 118.15%
Cash From Investing Activities $62.20M -$5.400M $52.70M
YoY Change 331.94% -110.25% 358.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 200.0K -93.20M 0.000
YoY Change -166.67% -100.0%
NET CHANGE
Cash From Operating Activities -47.40M -27.20M -21.80M
Cash From Investing Activities 62.20M -5.400M 52.70M
Cash From Financing Activities 200.0K -93.20M 0.000
Net Change In Cash 15.00M -125.8M 30.90M
YoY Change -153.38% -507.12% -405.94%
FREE CASH FLOW
Cash From Operating Activities -$47.40M -$27.20M -$21.80M
Capital Expenditures -$4.900M -$2.500M -$1.500M
Free Cash Flow -$42.50M -$24.70M -$20.30M
YoY Change 4.17% 21.67% 130.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q4 us-gaap Inventory Net
InventoryNet
12656000
CY2012Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
115168858 shares
CY2012Q3 nktr Amount Kept In Reserve Account
AmountKeptInReserveAccount
25000000
CY2012Q3 nktr Convertible Subordinated Notes Remaining
ConvertibleSubordinatedNotesRemaining
172400000
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43008000
CY2012Q1 nktr Base Interest Rate
BaseInterestRate
0.17 pure
CY2012Q2 nktr Base Interest Rate
BaseInterestRate
0.17 pure
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2012Q3 us-gaap Other Assets Current
OtherAssetsCurrent
7003000
CY2012Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2012Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
318961000
CY2012Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12687000
CY2012Q3 us-gaap Senior Long Term Notes
SeniorLongTermNotes
125000000
CY2012Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2012Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
155000
CY2012Q3 us-gaap Liabilities Current
LiabilitiesCurrent
69470000
CY2012Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
3586000
CY2012Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
22639000
CY2012Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1517454000
CY2012Q3 us-gaap Assets
Assets
541452000
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10338000
CY2012Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
12083000
CY2012Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3911000
CY2012Q3 us-gaap Inventory Net
InventoryNet
16754000
CY2012Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9728000
CY2012Q3 us-gaap Convertible Subordinated Debt Current
ConvertibleSubordinatedDebtCurrent
0
CY2012Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
308939000
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
541452000
CY2012Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
115073000 shares
CY2012Q3 us-gaap Common Stock Value
CommonStockValue
11000
CY2012Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q3 us-gaap Goodwill
Goodwill
76501000
CY2012Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
11870000
CY2012Q3 us-gaap Liabilities
Liabilities
446120000
CY2012Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6450000
CY2012Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1085000
CY2012Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73256000
CY2012Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
308939000
CY2012Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
115073000 shares
CY2012Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
101762000
CY2012Q3 us-gaap Assets Current
AssetsCurrent
346945000
CY2012Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q3 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
318961000
CY2012Q3 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
152000000
CY2012Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1612620000
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
95332000
CY2012Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
12414000
CY2012Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
10728000
CY2012Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2624000
CY2012Q3 nktr Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
10022000
CY2012Q3 nktr Cash And Cash Equivalents Including Restricted Cash
CashAndCashEquivalentsIncludingRestrictedCash
354300000
CY2012Q3 nktr Base Interest Rate
BaseInterestRate
0.17 pure
CY2012Q3 nktr Estimated Fair Value Of Cash Cash Equivalents And Available For Sale Investments
EstimatedFairValueOfCashCashEquivalentsAndAvailableForSaleInvestments
354299000
CY2012Q3 nktr Debt Instrument Convertible Retired Amount
DebtInstrumentConvertibleRetiredAmount
215000000
CY2012Q3 nktr License And Collaboration Agreements Potential Payments For Development Milestones
LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones
161100000
CY2012Q3 nktr Liability Related To Sale Of Potential Future Royalties
LiabilityRelatedToSaleOfPotentialFutureRoyalties
126746000
CY2012Q3 nktr Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
13200000
CY2012Q3 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2012Q3 nktr Liability Related To Sale Of Potential Future Royalties Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent
3000000
CY2012Q3 nktr Cash And Money Market Funds
CashAndMoneyMarketFunds
35338000
CY2012Q3 nktr Restricted Cash And Long Term Investments
RestrictedCashAndLongTermInvestments
35022000
CY2012Q3 nktr Liability Related To Sale Of Future Royalties Current And Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesCurrentAndNoncurrent
129746000
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17755000
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2011Q4 us-gaap Other Assets Current
OtherAssetsCurrent
17944000
CY2011Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2011Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
399624000
CY2011Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12807000
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1103000
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
275532000
CY2011Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1219000
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19643000
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1398525000
CY2011Q4 us-gaap Assets
Assets
606550000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15312000
CY2011Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
9754000
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4938000
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
114485000 shares
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
999000
CY2011Q4 us-gaap Convertible Subordinated Debt Current
ConvertibleSubordinatedDebtCurrent
214955000
CY2011Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
225856000
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
606550000
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2011Q4 us-gaap Goodwill
Goodwill
76501000
CY2011Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6486000
CY2011Q4 us-gaap Liabilities
Liabilities
408739000
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6669000
CY2011Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1683000
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
78576000
CY2011Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
213386000
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
114485000 shares
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
108188000
CY2011Q4 us-gaap Assets Current
AssetsCurrent
276706000
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2011Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
399624000
CY2011Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1597428000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
197811000
CY2011Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
14582000
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
10437000
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3019000
CY2011Q4 nktr Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
186238000
CY2011Q4 nktr Estimated Fair Value Of Cash Cash Equivalents And Available For Sale Investments
EstimatedFairValueOfCashCashEquivalentsAndAvailableForSaleInvestments
414936000
CY2011Q4 nktr Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
11953000
CY2011Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
3100000 shares
CY2011Q4 nktr Cash And Money Market Funds
CashAndMoneyMarketFunds
15312000
CY2011Q4 nktr Restricted Cash And Long Term Investments
RestrictedCashAndLongTermInvestments
173768000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-599000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2681000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1750000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.86
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-126353000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1583000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
93464000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.32 pure
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12320000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12188000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-96183000
us-gaap Interest Paid
InterestPaid
9592000
us-gaap Share Based Compensation
ShareBasedCompensation
14501000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
11424000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
25253000
us-gaap Available For Sale Securities Gross Realized Gains Losses Sale Proceeds
AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds
218700000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
218660000
us-gaap Operating Income Loss
OperatingIncomeLoss
-89469000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
967000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-3388000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
16441000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1431000
us-gaap Net Income Loss
NetIncomeLoss
-96483000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6714000
us-gaap Costs And Expenses
CostsAndExpenses
145167000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
2508000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35262000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
222641000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-98438000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
290810000
us-gaap Revenues
Revenues
55698000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
493000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8294000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
627529000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14501000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11423000 shares
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
6238000
us-gaap Interest Expense
InterestExpense
7698000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4200000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
224072000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-71528000
nktr Product Sales And Royalties
ProductSalesAndRoyalties
26023000
nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
29675000
nktr Increase Decrease In Accrued Clinical Trial Expenses
IncreaseDecreaseInAccruedClinicalTrialExpenses
1468000
nktr Weighted Average Shares Outstanding Used In Computing Basic And Diluted Net Loss Per Share
WeightedAverageSharesOutstandingUsedInComputingBasicAndDilutedNetLossPerShare
112435000 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2012-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0000906709
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Trading Symbol
TradingSymbol
NKTR
dei Entity Registrant Name
EntityRegistrantName
NEKTAR THERAPEUTICS
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
913000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1309000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
10593000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.04
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
50793000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1865000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
4400000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
102302000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.32 pure
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3430000
us-gaap Repayments Of Subordinated Debt
RepaymentsOfSubordinatedDebt
172407000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1027000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-118490000
us-gaap Interest Paid
InterestPaid
9010000
us-gaap Share Based Compensation
ShareBasedCompensation
12015000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
10595000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4974000
us-gaap Available For Sale Securities Gross Realized Gains Losses Sale Proceeds
AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds
5400000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
5378000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-20670000
us-gaap Costs And Expenses
CostsAndExpenses
157865000
us-gaap Operating Income Loss
OperatingIncomeLoss
-97820000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
641000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-4098000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
23138000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1773000
us-gaap Net Income Loss
NetIncomeLoss
-118929000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-120000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30750000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26591000
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
78006000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-117671000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
202768000
us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Investments in securities with remaining maturities of less than one year, or where our intent is to use the investments to fund current operations or to make them available for current operations, are classified as short-term investments.
us-gaap Revenues
Revenues
60045000
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
42548000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-25000000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
439000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
22000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5744000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1675000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
126609000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12015000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13836000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. On an ongoing basis, we evaluate our estimates, including those related to deferred revenue recognition periods, inventories, the impairment of investments, the impairment of goodwill and long-lived assets, contingencies, estimated interest expense from our liability related to our sale of future royalties, stock-based compensation, and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.</font></p> </div>
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-465000
us-gaap Interest Expense
InterestExpense
23448000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-401000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3177000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-82380000
nktr Number Of Business Segments
NumberOfBusinessSegments
1 Segment
nktr Redemption Price As Percentage Of Principal Amount In Case Of Change Of Control
RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl
1.01 pure
nktr Royalties Remitted To Purchaser
RoyaltiesRemittedToPurchaser
6895000
nktr Product Sales And Royalties
ProductSalesAndRoyalties
35855000
nktr Proceeds From Sale Of Potential Future Royalties
ProceedsFromSaleOfPotentialFutureRoyalties
124000000
nktr Proceeds From Sale Of Potential Future Royalties Net Of Transaction Costs
ProceedsFromSaleOfPotentialFutureRoyaltiesNetOfTransactionCosts
119588000
nktr Noncash Interest Expense
NoncashInterestExpense
12856000
nktr Noncash Interest Expense On Liability From Sale Of Royalties
NoncashInterestExpenseOnLiabilityFromSaleOfRoyalties
12641000
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
6895000
nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
24190000
nktr Increase Decrease In Accrued Clinical Trial Expenses
IncreaseDecreaseInAccruedClinicalTrialExpenses
1247000
nktr Weighted Average Shares Outstanding Used In Computing Basic And Diluted Net Loss Per Share
WeightedAverageSharesOutstandingUsedInComputingBasicAndDilutedNetLossPerShare
114699000 shares
nktr Debt Instrument Maximum Maturity Period
DebtInstrumentMaximumMaturityPeriod
Two years or less
CY2012Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2011Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-717000
nktr Debt Instrument Weighted Average Maturity Period1
DebtInstrumentWeightedAverageMaturityPeriod1
One year or less
nktr Redemption Price As Percentage Of Principal Amount In Case Of Sale Of Assets
RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets
1.00 pure
nktr Payment For Transaction Costs
PaymentForTransactionCosts
4400000
CY2012Q3 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
82500000
CY2012Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1675000
CY2011Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2011Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
622000
CY2011Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31018000
CY2011Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.32 pure
CY2011Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-23976000
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21338000
CY2011Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5038000
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
-24068000
CY2011Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2638000
CY2011Q3 us-gaap Costs And Expenses
CostsAndExpenses
48406000
CY2011Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12350000
CY2011Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25821000
CY2011Q3 us-gaap Revenues
Revenues
27068000
CY2011Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
92000
CY2011Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4819000
CY2011Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14471000 shares
CY2011Q3 us-gaap Interest Expense
InterestExpense
2543000
CY2011Q3 nktr Product Sales And Royalties
ProductSalesAndRoyalties
10222000
CY2011Q3 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
16846000
CY2011Q3 nktr Weighted Average Shares Outstanding Used In Computing Basic And Diluted Net Loss Per Share
WeightedAverageSharesOutstandingUsedInComputingBasicAndDilutedNetLossPerShare
114413000 shares
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
156000
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2012Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
603000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34016000
CY2012Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.32 pure
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-43325000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-32900000
CY2012Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7228000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-43547000
CY2012Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10425000
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
51312000
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10068000
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42772000
CY2012Q3 us-gaap Revenues
Revenues
18412000
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
222000
CY2012Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3980000
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14301000 shares
CY2012Q3 us-gaap Interest Expense
InterestExpense
11184000
CY2012Q3 nktr Proceeds From Issuance Of Senior Notes
ProceedsFromIssuanceOfSeniorNotes
125000000
CY2012Q3 nktr Product Sales And Royalties
ProductSalesAndRoyalties
12280000
CY2012Q3 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
6132000
CY2012Q3 nktr Weighted Average Shares Outstanding Used In Computing Basic And Diluted Net Loss Per Share
WeightedAverageSharesOutstandingUsedInComputingBasicAndDilutedNetLossPerShare
114915000 shares
CY2012Q3 nktr Dilutive Securities Convertible Notes And Securities Shares
DilutiveSecuritiesConvertibleNotesAndSecuritiesShares
0 shares

Files In Submission

Name View Source Status
0001193125-12-463220-index-headers.html Edgar Link pending
0001193125-12-463220-index.html Edgar Link pending
0001193125-12-463220.txt Edgar Link pending
0001193125-12-463220-xbrl.zip Edgar Link pending
d410718d10q.htm Edgar Link pending
d410718dex311.htm Edgar Link pending
d410718dex312.htm Edgar Link pending
d410718dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
nktr-20120930.xml Edgar Link completed
nktr-20120930.xsd Edgar Link pending
nktr-20120930_cal.xml Edgar Link unprocessable
nktr-20120930_def.xml Edgar Link unprocessable
nktr-20120930_lab.xml Edgar Link unprocessable
nktr-20120930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending